¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor volume"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
¿µ¹® tumor ÇÑ±Û Á¾¾ç
¼³¸í   
  Á¶ÀýÇÒ ¼ö ¾øÀÌ °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë. ½Å»ý¹°.
  
  (1) ºÐ·ù
  
    A. Ä§À±°ú ÀüÀÌÀÇ À¯¹«¿¡ µû¶ó
  
      i)¾ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ¾ø°í ¿ªÇü¼ºÀÌ ³·Àº ¼¼Æ÷·Î ±¸¼ºµÊ. ´ë°³ Ä¡·á¿¡ ¹ÝÀÀÀÌ ³ô°í, »ý¸í¿¡ Å©°Ô ÁöÀåÀÌ ¾øÀ¸¸ç, Àç¹ßÇϴ °æ¿ìµµ Àû´Ù. Áõ»óÀº ´ÜÁö ÁÖÀ§Á¶Á÷¿¡ ´ëÇÑ ¾Ð¹ÚÁ¤µµÀÌ´Ù.
  
      ii)¾Ç¼ºÁ¾¾ç: Ä§À±°ú ÀüÀ̰¡ ÀÖ°í ÅðÈ­µµ°¡ ³ôÀº ¼¼Æ÷·Î ±¸¼ºµÊ. ±â¿ø¼¼Æ÷°¡ »óÇÇÁ¶Á÷ÀÏ °æ¿ì ¾ÏÁ¾, ºñ»óÇǼºÀÏ °æ¿ì À°Á¾À¸·Î ³ª´©±âµµ ÇÑ´Ù. Ä¡·á¿¡ Àß ¹ÝÀÀÇÏÁö ¾Ê°í, Àç¹ßÀ» Àß Çϸç, »ýÁ¸À²ÀÌ ³·´Ù. ÈçÈ÷ ¸»Çϴ ¡°¾Ï¡±À» ÀǹÌÇÑ´Ù.
  
    B. Á¶Á÷ÇÐÀû Æ¯Â¡¿¡ µû¶ó »ùÁ¾, Áö¹æÁ¾, ±ÙÁ¾ µîÀ¸·Î ³ª´©±âµµ ÇÑ´Ù.
  
  (2) º´¸®Á¶Á÷ÇÐÀû Æ¯Â¡
  
    A. À°¾ÈÀû ¼Ò°ß
  
  µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ Çϰí Á¤»óÁ¶Á÷¿¡ ½º¸çµéµíÀÌ ÆÇ»ó±¸Á¶¸¦ ÀÌ·ç±âµµ Çϴ µî ´Ù¾çÇÑ ÇüŸ¦ º¸ÀδÙ. ¾ç¼ºÀÇ °æ¿ì ÇǸ·À» °¡Áø °æ¿ì°¡ ¸¹°í ¾Ç¼ºÀÇ °æ¿ì ¾ø´Â °æ¿ì°¡ ¸¹´Ù.
  
  À°¾È¼Ò°ß¿¡ µû¶ó ´ÙÀ½°ú °°ÀÌ ³ª´«´Ù. ³¶¼º, À¶±â¼º, ±«»ç¼º, Æú¸³¸ð¾ç, ±Ë¾çÇü µîÀÌ ÀÖ´Ù. ¶Ç´Â ¼¼Æ÷ÀÇ Å©±â¿Í ¸ð¾çÀÌ ºñÁ¤»óÀûÀΠÇüÅ·Πº¯È­ÇÑ´Ù. ÇÙÀÇ ±Ø¼ºÀÌ »ç¶óÁö°í ÇÙÀÇ ¿°»ö¼ºÀ̠£¾îÁø´Ù. ¼¼Æ÷ÁúÀÇ ¿°»ö¼ºµµ º¯È­Çϸ砼¼Æ÷µé°£ÀÇ ¼¼Æ÷ÁֱⰡ ¸Å¿ì ´Ù¾çÇØÁ® ¸¹Àº ¼¼Æ÷ºÐ¿­À» º¸ÀδÙ. ÀÌ·¯ÇÑ ÀÏ·ÃÀÇ º¯È­¸¦ ¿ªÇü¼ºÀ̶ó ÇÑ´Ù. ¿ªÇü¼ºÀÇ Á¤µµ¿¡ µû¶ó Á¶Á÷ÇÐÀû µî±ÞÀ» ³ª´«´Ù. ¶ÇÇÑ °¢ Á¾¾ç¿¡ µû¶ó °¢±â ´Ù¸¥ º´¸®Á¶Á÷ÇÐÀû ¸íĪÀ» ºÙÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • volume of distribution
    ºÐÆ÷¿ëÀû
  • volume overload
    ¿ëÀû°úºÎÇÏ
  • volume pulse
    ¿ëÀû¸Æ¹Ú
  • volume receptor
    ¿ëÀû¼ö¿ë±â
  • volume-cycled ventilator
    ¿ëÀûÁÖ±âÇüȯ±â±â
  • adenomatoid odontogenic tumor
    »ùÁ¾¸ð¾çÄ¡¿ø¼ºÁ¾¾ç
  • adenomatoid tumor
    »ùÁ¾¸ð¾çÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • collision tumor
    Ãæµ¹Á¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶¼ºÁ¾¾ç
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • Ewing¡¯s tumor
    À¯À×Á¾¾ç
  • embryonal tumor
    ¹è¾Æ¼ºÁ¾¾ç
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç, ³»¹è¿±µ¿Á¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • endodermal sinus tumor
    ³»¹è¿±±¼Á¾¾ç
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
  • neuroepithelial tumor
    ½Å°æ»óÇÇÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´ÉÁ¾¾ç
  • occult primary tumor
    Àẹ¿ø¹ßÁ¾¾ç
  • odontogenic tumor
    Ä¡¾ÆÅ¿Á¾¾ç, Ä¡¿øÁ¾¾ç
  • peripheral primitive neuroectodermal tumor
    ¸»ÃÊ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
  • phyllodes tumor
    ¿±»óÁ¾¾ç
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • phonatory air volume
    ¹ß¼º½Ã°ø±â·®
  • planning target volume
    °èȹǥÀûºÎÇÇ
  • pressure volume relation
    ¾Ð·Â¿ëÀû°ü°è
  • volume pulse
    ¿ëÀû¸Æ¹Ú
  • relative osteoid volume
    »ó´ëÀ¯°ñ·®
  • residual volume
    Àܱⷮ, ³²Àº°ø±â·®
  • volume receptor
    ¿ëÀû¼ö¿ëü
  • stroke volume
    ÀÏȸ¹ÚÃâ·®
  • volume speed
    ºÎÇÇÁö¼Óµµ, ¿ëÀûÁö¼Óµµ
  • volume magnetic susceptibility
    ¿ëÀûÀÚ±âÈ­À²
  • throughput volume
    ¿Ï·á·®
  • tidal volume
    ÀÏȸȣÈí·®
  • total volume urine
    Ãѹ财·®
  • volume gradient echo technique
    ¿ëÀû±â¿ï±â¿¡ÄÚ±â¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • Leydig cell tumor
    ·¹À̵ðÈ÷¼¼Æ÷Á¾¾ç
  • Schwann cell tumor
    ½´¹Ý¼¼Æ÷Á¾¾ç
  • TNF => tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • Warthins tumor
    ¿Í¸£Æ¾ Á¾¾ç
  • Warthins tumor => adenolymphoma
    ¼±¸²ÇÁÁ¾
  • Wilms tumor
    Àª¸§Á¾¾ç
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • acoustic tumor
    û½Å°æÁ¾¾ç
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
  • adenomatoid tumor
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), À¯¼±Á¾Á¾¾ç(×¾àÍðþðþåË)
  • adenomatoid tumor, tubal
    ¼±Á¾¾çÁ¾¾ç(àÍðþåÆðþåË), ³­°ü(Ñëη)ÀÇ
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal rest tumor
    ºÎ½ÅÀÜÀ¯Á¾¾ç
  • adrenal tumor
    ºÎ½ÅÁ¾¾ç(ÜùãìðþåË).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • end-diastolic volume
    È®Àå±â¸»¿ëÀû(¡­éÄîÝ)
  • end-systolic volume
    ¼öÃà±â¸»¿ëÀû(¡­éÄîÝ)
  • enddiastolic volume
    È®À帻±â¿ëÀû.
  • erythrocyte volume measurement
    ÀûÇ÷±¸¿ëÀûÃøÁ¤
  • expiratory reserve volume =ERV
    È£½Ä¼º ¿¹ºñ¿ëÀû(û¼ãÓàõçãÝáé»îÝ). ¸¶ Ãë È£±â¿¹ºñ·®, ¿¹ºñÈ£±â
  • expiratory reserve volume =ERV
    È£±â¿¹ºñ·®, ¿¹ºñÈ£±â·®, È£½Ä¼º ¿¹ºñ¿ëÀû
  • extracellular liquid volume
    ¼¼Æ÷¿Ü¾×·®(¡­äûåÖ).
  • flow volume curve
    À¯·®¿ë·®°î¼±(êüÕáé»ÕáÍØàÊ).
  • flow-volume curve
  • forced expiratory volume
    °­Á¦È£±â(ÆóȰ)·®, ³ë·ÂÈ£±âÆóȰ·®
  • forced expiratory volume = FEV
    °­Á¦È£±â(ÆóȰ)·®, ³ë·ÂÈ£±âÆóȰ·®
  • forced expiratory volume =FEV
    °­Á¦È£±â(ÆóȰ(øËüÀ))·®, ³ë·ÂÈ£±âÆóȰ·®(Ò½æ³ û¼Ñ¨øËüÀåÖ).
  • forced expiratory volume =FEV
    °­Á¦È£±â(ÆóȰ)·®, ³ë·ÂÈ£±âÆóȰ·®
  • forced inspiratory volume =FIV
    <ÃÖ´ë>³ë·ÂÈí±âÆóȰ·®(<õÌÓÞ>Ò½æ³ýåѨøËüÀåÖ).
  • forced inspiratory volume =FIV
    <ÃÖ´ë>³ë·ÂÈí±âÆóȰ·®(<õÌÓÞ>Ò½æ³
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • metastatic tumor
    ÀüÀ̼ºÁ¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mucoepidermoid tumor
    Á¡¾×Ç¥ÇǾçÁ¾¾ç
  • mucous tumor
    Á¡¾×Á¾
  • nasopharyngeal tumor
    ºñÀεÎÁ¾¾ç
  • neurogenic tumor
    ½Å°æ(¿ø)¼ºÁ¾¾ç
  • nonfunctioning tumor
    ºñ±â´É¼ºÁ¾¾ç
  • odontogenic tumor
    Ä¡(¿ø)¼ºÁ¾¾ç
  • ovarian tumor
    ³­¼ÒÁ¾¾ç
  • papillary tumor
    À¯µÎ»ó Á¾¾ç
  • phantom tumor
    ȯ»óÁ¾¾ç
  • primary tumor
    ¿ù¹ßÁ¾¾ç
  • solid tumor
    Ãæ½Ç¼ºÁ¾¾ç
  • superior sulcus tumor
    »ó±¸Á¾¾ç
  • supratentorial tumor
    õ¸·»óÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
GCT general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor
ICT icteric, icterus; indirect Coombs test; inflammation of connective tissue; insulin coma therapy; int...
JGCT juvenile granulosa cell tumor; juxtaglomerular cell tumor
MTV mammary tumor virus; metatarsus varus; mouse mammary tumor virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DVH Dose Volume Histogram
EDV End Diastolic Volume
ESV End Systolic volume
EDVi End diastolic volume index
EELV End-expiratory lung volume
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • volume overload
    Ç÷·® °úºÎÇÏ
  • volume receptor
    ¿ëÀû ¼ö¿ë±â
  • volume sensitive respirator
    Á¦·® ÀΰøÈ£Èí±â, ¿ë·® Á¦ÇÑ ÀΰøÈ£Èí±â
  • weight/volume percent
    üÁß/¿ëÀû ·ü
  • acoustic tumor
    û½Å°æ Á¾¾ç
    Á¦ 8 ½Å°æ¿¡¼­ »ý±ä ¾ç¼º Á¾¾ç.
  • ACTH-secreting tumor
    ACTH-ºÐºñ Á¾¾ç
    µ¿ÀǾî=corticotro
  • adenomatoid tumor
    ¼± Á¾¾ç Á¾¾ç, À¯¼±Á¾ Á¾¾ç
    ¼ºÀå ¼Óµµ°¡ ´À¸° ÀÛÀº °áÀýÇüÀÇ ¾ç¼º Á¾¾çÀ̳ª ¶§·Î´Â ¼ö cm±îÁö µÉ ¼ö ÀÖ´Ù. ÀÌ Á¾¾çÀº ºÎ°íȯ Á¾¾ç Áß °¡Àå ÈçÇÏ¸ç ¿©ÀÚ¿¡¼­µµ Àڱà ¶Ç´Â ¼ö¶õ°üÀÇ À帷Ãþ¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
  • adrenal cortex tumor
    ºÎ½Å ÇÇÁú Á¾¾ç
  • amelanotic tumor
    ¹«¸á¶ó´Ñ Á¾¾ç
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • benign melanocytic tumor
    ¾ç¼º ¸á¶ó´Ñ ¼¼Æ÷Á¾
  • benign vascular tumor
    ¾ç¼º Ç÷°üÁ¾
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bladder tumor
    ¹æ±¤ Á¾¾ç
    ¹æ±¤ º®ÀÇ °¢ Á¶Á÷¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. À¯µÎÁ¾, ¼±Á¾, ±ÙÁ¾, ÇǺξçÁ¾, Áö¹æÁ¾, Ç÷°üÁ¾ µî ¾ç¼ºÀÎ °Í°ú ¾Ï, À°Á¾ µî ¾Ç¼ºÀÎ °ÍÀÌ ÀÖÀ¸¸ç, ¾à 10 %¸¸ÀÌ ¾ç¼ºÀÌ°í ´ëºÎºÐÀÌ ¾Ç¼ºÀ¸·Î ¹ß»ý ¿øÀÎÀº ºÒ¸íÀÌ´Ù. ƯÁ¤ ±âÈ£ À½·á³ª ¾à¹°ÀÇ Àå±â ¿¬¿ë µî¿¡ ÀÇÇÏ´Â °Í°ú ¾Æ´Ò¸°°è ¾àǰÀ» Ãë±ÞÇÏ´Â °øÀå ±Ù·ÎÀÚ¿¡°Ô¼­ º¸°Ô µÇ´Â Á÷¾÷ ¾ÏÀÌ ÁÖ¸ñµÇ°í ÀÖ´Ù. ¶ÇÇÑ ¹æ±¤ Á¾¾çÀº Áß³â ÀÌÈÄ¿¡ Àß ¹ß»ýµÇ¸ç ¿©ÀÚº¸´Ù ³²ÀÚ¿¡°Ô ¸¹´Ù. Ãʱâ Áõ¼¼´Â Ç÷´¢¸¦ º¸ÀÌ´Ù°¡ ÀúÀý·Î ¸ÜÀ¸¸ç, ÀÌ·± ÀÏÀÌ ¹Ýº¹µÇ´Â µ¿¾È¿¡ ¹æ±¤¿°, ½Å¿ì½Å¿°À» º´¹ßÇÏ¿© ¹è´¢Åë, ºó´¢, Ç÷³ó´¢¿Í ¿äÅëÀÌ ³ªÅ¸³­´Ù. ¶§·Î´Â ¹æ±¤ ¾È¿¡ ÀÀÇ÷ÀÌ »ý±â°í ¹æ±¤ Ãⱸ¿¡ Á¾¾çÀÌ »ý°Ü ¹è´¢ Àå¾Ö°¡ ¿À±âµµ ÇÑ´Ù. ¹æ±¤°æ °Ë»ç·Î Áø´ÜÇϸç, ħÀ±¼ºÀÌ °­ÇϹǷΠÁ¶±â Áø´Ü ¹× Á¶±â Ä¡·á°¡ ¹Ù¶÷Á÷ÇÏ´Ù. Ä¡·á¹ýÀ¸·Î´Â ¿©·¯ °¡Áö ºñ´¢±â°úÀû ¼ö¼ú¹ý°ú ¹æ»ç¼± ¿ä¹ýÀÌ ÀÖÀ¸¸ç, Á¾¾çÀÇ ¼º»ó°ú ȯÀÚÀÇ ¿¬·É ¹× Àü½Å »óÅ µî¿¡ µû¶ó¼­ ÀÌ µÎ °¡Áö¸¦ Àû´çÈ÷ ¼¯¾î Ä¡·áÇÏ´Â Ä¡·á¹ýÀ» »ç¿ëÇÑ´Ù. ¾Ç¼ºÀÎ °æ¿ì ¹æÄ¡Çϸé ÇÒ¼ö·Ï ¹æ±¤ÀÇ ÁÖº¯ ¹× ¸Ö¸® ¶³¾îÁø ºÎÀ§¿¡µµ ÀüÀÌÇÏ¿© Ä¡À¯µÇ±â ¾î·Á¿öÁø´Ù. Àç¹ßÇϱ⠽¬¿î ÁúȯÀ̹ǷΠġ·á ÈÄ¿¡µµ 1³â¿¡ 3ȸ Á¤µµ ¹Ý¿µ±¸ÀûÀ¸·Î Á¤±â °ËÁøÀ» ¹Þ¾Æ¾ß Çϸç, Ç÷´¢°¡ ³ªÅ¸³ª¸é Áï½Ã ÁøÂûÀ» ¹Þµµ·Ï ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
stroke volume <physiology> The amount of blood pumped out of one ventricle of the heart as the result of a single contraction. A measure of the effectiveness of ventricular contraction.
(16 Dec 1997)
distribution volume The volume throughout which an added tracer substance appears to have been evenly distributed, calculated by dividing the amount of tracer added by its concentration after equilibration.
(05 Mar 2000)
inspiratory reserve volume The extra volume of air that can be inspired with maximal effort after reaching the end of a normal, quiet inspiration. Common abbreviation is irv.
(12 Dec 1998)
interstitial lung disease with increased volume <radiology> Cystic fibrosis (CF), eosinophilic granuloma (EG), lymphangioleiomyomatosis (LAM)
(12 Dec 1998)
tidal volume The volume of air inspired or expired during each normal, quiet respiratory cycle. Common abbreviations are tv or v with subscript t.
(12 Dec 1998)
elution volume <chemistry> The amount of eluant which has passed through the column in column chromatography before a particular peak in an elution profile appears, or before a specific substance of interest comes out with the eluant, separated out of the original mixed substance.
(09 Oct 1997)
end-diastolic volume The amount of blood in the ventricle immediately before a cardiac contraction begins; a measurement of cardiac filling between beats, related to diastolic function.
(05 Mar 2000)
end-systolic volume The amount of blood in the ventricle at the end of the cardiac ejection period and immediately preceding the beginning of ventricular relaxation; a measurement of the adequacy of cardiac emptying, related to systolic function.
(05 Mar 2000)
erythrocyte volume Volume of circulating erythrocytes. It is usually measured by radioisotope dilution technique.
(12 Dec 1998)
expiratory reserve volume The extra volume of air that can be expired with maximum effort beyond the level reached at the end of a normal, quiet expiration. Common abbreviation is erv.
(12 Dec 1998)
extracellular fluid volume The fraction of body wate rnot in cells; about 25% of body weight. It consists of plasma water (4.5% of body weight), water between cells (interstitial water-lymph, 11.5% of body weight), water in dense bone and connective tissue (7.5% of body weight) and water secretions.See transcellular water, about 1.5% of body weight..
(05 Mar 2000)
flow-volume curve The graph produced by plotting the instantaneous flow of respiratory gas against the simultaneous lung volume, usually during maximal forced expiration.
(05 Mar 2000)
foliage volume <botany> The space, expressed in cubic metres, occupied by a tree.
(12 Nov 1997)
forced expiratory volume Measure of the maximum amount of air during a forced vital capacity determination that can be expelled in a given number of seconds. It is usually given as fev followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity.
(12 Dec 1998)
left ventricular volume overload <radiology> VSD, patent ductus arteriosus, mitral incompetence, aortic incompetence
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á